IL6 and susceptibility to pneumonia measurement: Furthermore, a small retrospective observational study conducted in China [29] suggests the efficacy of tocilizumab (an IL-6 inhibitor) in the treatment of 21 COVID-19 patients with severe pneumonia and high IL-6.